
European Commission approves AbbVie’s RINVOQ® for treatment of Giant Cell Arteritis
NORTH CHICAGO- April 2025- AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients. RINVOQ is the first and only oral …